Results from a compound screen on 84 NSCLC cell lines.
For purpose of computational, lesion-based prediction of compound
activity in 84 non-small cell lung cancer (NSCLC) cell lines, these
were treated with a selection of compounds to measure the respective
concentration where 50 per cent of cell growth was inhibited after a
predefined time period. Most of the screening experiments were
performed on 384 (16 x 24)-well plates, were the experimental setup was
designed according to the arrangement in the files
"mpi384_dilution.txt" that are installed together with the
These data sets are the direct output from a signal reader of the 384-well plates for the A549, Calu1, H322 and H2429 cancer cell lines selected from the 84 NSCLC cell lines collection. A tab-delimited version is installed together with the package.
Frommolt P, Thomas RK (2008): Standardized high-throughput evaluation of cell-based compound screens. BMC Bioinformatics, 9(1): 475
Sos ML, Michel K, Zander T, Weiss J, Frommolt P, et al. (2009): Predicting drug susceptibility in non-small cell lung cancers based on genetic lesions. J Clin Invest, 119(6): 1727-40
Want to suggest features or report bugs for rdrr.io? Use the GitHub issue tracker.